Title : Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats.

Pub. Date : 2019 Feb

PMID : 30508725






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. Pioglitazone peroxisome proliferator-activated receptor gamma Rattus norvegicus
2 The aim of the present study was to evaluate whether PPARG activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in early ovarian function induced by androgen excess. Pioglitazone peroxisome proliferator-activated receptor gamma Rattus norvegicus
3 The aim of the present study was to evaluate whether PPARG activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in early ovarian function induced by androgen excess. Pioglitazone peroxisome proliferator-activated receptor gamma Rattus norvegicus
4 RESULTS: PGZ prevented the inactivation of ovarian PPARG induced by androgen excess by increasing PPARG itself and the gene expression of PPARG-coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-repressor (NCOR). Pioglitazone peroxisome proliferator-activated receptor gamma Rattus norvegicus
5 RESULTS: PGZ prevented the inactivation of ovarian PPARG induced by androgen excess by increasing PPARG itself and the gene expression of PPARG-coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-repressor (NCOR). Pioglitazone peroxisome proliferator-activated receptor gamma Rattus norvegicus